Korea Biomedical Review | EuBiologics remains alert to respond to Turkey, Syria crisis amid global cholera vaccine shortage
Korea Biomedical Review | EuBiologics remains alert to respond to Turkey, Syria crisis amid global cholera vaccine shortage
2023. 2. 16, 코리아 바이오메디칼 리뷰
Furthermore, IVI is currently engaged in the clinical development of an injection-type cholera vaccine called EuCCV together with EuBiologics which can be used for children younger than one-year-old for which the current OCV vaccine does not cover.
“The cholera conjugate vaccine is currently in phase 1 clinical trials with support from the RIGHT Foundation at three hospital trial centers domestically and trial results are expected in 2024,” said Director of IVI’s Cholera Program, Dr. Julia Lynch. “However, phase 2 and 3 trials will be conducted in cholera-endemic countries.”
